{"result": "(\"entity\"<|>EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY<|>ORGANIZATION<|>The European Society for Paediatric Endocrinology (ESPE) provides guidelines for the treatment of congenital hypothyroidism, emphasizing the importance of early treatment with levotiroxine.)\n##\n(\"entity\"<|>LEVOTIROXINE<|>ORGANIZATION<|>Levotiroxine is a medication used as the primary treatment for congenital hypothyroidism, recommended by ESPE.)\n##\n(\"entity\"<|>TRIIODOTHYRONINE<|>ORGANIZATION<|>Triiodothyronine is a hormone that is sometimes combined with levotiroxine in treatment, though ESPE recommends using levotiroxine alone.)\n##\n(\"entity\"<|>HYPOTHYROIDISM<|>EVENT<|>Hypothyroidism is a condition that can occur in newborns due to congenital issues, requiring early treatment for normal development.)\n##\n(\"entity\"<|>BIRTH<|>EVENT<|>Birth is a critical time for the initiation of treatment for congenital hypothyroidism, ideally within the first two weeks of life.)\n##\n(\"entity\"<|>DIMITROPOULOS A<|>PERSON<|>Dimitropoulos A is one of the authors referenced in the studies regarding long-term outcomes of children with congenital hypothyroidism.)\n##\n(\"entity\"<|>MOLINARI L<|>PERSON<|>Molinari L is another author referenced in the studies regarding long-term outcomes of children with congenital hypothyroidism.)\n##\n(\"entity\"<|>ETTER K<|>PERSON<|>Etter K is one of the authors referenced in the studies regarding long-term outcomes of children with congenital hypothyroidism.)\n##\n(\"entity\"<|>TORRESANI T<|>PERSON<|>Torresani T is one of the authors referenced in the studies regarding long-term outcomes of children with congenital hypothyroidism.)\n##\n(\"entity\"<|>LANG-MURITANO M<|>PERSON<|>Lang-Muritano M is one of the authors referenced in the studies regarding long-term outcomes of children with congenital hypothyroidism.)\n##\n(\"entity\"<|>JENNI OG<|>PERSON<|>Jenni OG is one of the authors referenced in the studies regarding long-term outcomes of children with congenital hypothyroidism.)\n##\n(\"relationship\"<|>EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY<|>LEVOTIROXINE<|>The European Society for Paediatric Endocrinology recommends levotiroxine as the primary treatment for congenital hypothyroidism<|>9)\n##\n(\"relationship\"<|>LEVOTIROXINE<|>TRIIODOTHYRONINE<|>Levotiroxine is often discussed in relation to triiodothyronine as a treatment option for hypothyroidism<|>5)\n##\n(\"relationship\"<|>HYPOTHYROIDISM<|>BIRTH<|>The onset of hypothyroidism treatment is critical immediately after birth for effective management<|>8)\n##\n(\"relationship\"<|>DIMITROPOULOS A<|>EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY<|>Dimitropoulos A is referenced in studies that align with the guidelines set by the European Society for Paediatric Endocrinology<|>6)\n##\n(\"relationship\"<|>MOLINARI L<|>EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY<|>Molinari L is referenced in studies that align with the guidelines set by the European Society for Paediatric Endocrinology<|>6)\n##\n(\"relationship\"<|>ETTER K<|>EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY<|>Etter K is referenced in studies that align with the guidelines set by the European Society for Paediatric Endocrinology<|>6)\n##\n(\"relationship\"<|>TORRESANI T<|>EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY<|>Torresani T is referenced in studies that align with the guidelines set by the European Society for Paediatric Endocrinology<|>6)\n##\n(\"relationship\"<|>LANG-MURITANO M<|>EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY<|>Lang-Muritano M is referenced in studies that align with the guidelines set by the European Society for Paediatric Endocrinology<|>6)\n##\n(\"relationship\"<|>JENNI OG<|>EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY<|>Jenni OG is referenced in studies that align with the guidelines set by the European Society for Paediatric Endocrinology<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: otiroidismo congénito, ¿cuál de las siguientes respuestas es cierta?\n\nA. El tratamiento inicial de elección es la terapia combinada con levotiroxina (10-15 µg por kg de peso) y triyodotironina (3,125 µg cada 12 h).\nB. Se debe posponer el tratamiento sustitutivo hasta tener los resultados de las pruebas de imagen, sobre todo las de medicina nuclear.\nC. En los defectos de las deshalogenasas (codificadas por el gen IYD) puede aparecer bocio.\nD. La presencia de bocio descarta alteraciones en la proteína transportadora de yodo NIS (Na/I symporter).\n\n### COMENTARIO\n\nEn relación con la primera opción a la pregunta, la Guía de la European Society for Paediatric Endocrinology de 2014 (ESPE) establece que el fármaco de elección para el tratamiento del hipotiroidismo congénito es la levotiroxina aislada. En efecto, aunque la T3 sea la hormona biológicamente activa, no hay ninguna evidencia de que el tratamiento combinado de T4 y T3 sea más efectivo que la T4 sola, por lo que se recomienda usar únicamente la T4 como tratamiento (opción A falsa).\n\nEl inicio temprano del tratamiento con levotiroxina, dentro de las dos primeras semanas de vida, es crucial para un desarrollo neurológico normal y es un factor determinante para que el niño afectado adquiera un desarrollo intelectual normal. En este aspecto, la misma\n---\n# TIROIDES\n\nGuía ESPE establece que el tratamiento del hipotiroidismo congénito debería empezar tan pronto como sea posible y no más tarde de las 2 semanas de vida (opción B falsa).\n\nLos defectos enzimáticos en la síntesis de hormonas tiroideas son la segunda causa más frecuente, después de las disgenesias tiroideas, de hipotiroidismo congénito. Estos defectos pueden afectar a la proteína transportadora de yodo (NIS), a la peroxidasa tiroidea, a la tiroglobulina o a las deshalogenasas tiroideas. Las manifestaciones clínicas de estos defectos incluyen grados variables de hipotiroidismo, así como presencia de hiperplasia tiroidea para intentar compensar la deficiencia en la síntesis de hormonas tiroideas. Por lo tanto, la opción C es correcta, ya que en los defectos de deshalogenasas tiroideas (dishormonogénesis de tipo 4) puede aparecer bocio. Sin embargo, y por el mismo motivo, en las alteraciones del NIS puede aparecer bocio (opción D falsa).\n\nReferencias:\n- Dimitropoulos A, Molinari L, Etter K, Torresani T, Lang-Muritano M, Jenni OG, et al. Children with congenital hypothyroidism: long-term intellectual outcome after early high-dose treatment. Pediatr Res. 2009;65:242-8.\n- Grasberger H, Refetoff S. Genetic causes of congenital hypothyroidism due to dyshormonogenesis. Curr Opin Pediatr. 2011;23:421-8.\n- Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2006;91:2592-9.\n- LaFranchi SH. Approach to the diagnosis and treatment of neonatal hypothyroidism. J Clin Endocrinol Metab. 2011;96:2959-67.\n- Leger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, et al, on behalf of ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE, and the Congenital Hypothyroidism Consensus Conference Group. European Society for Paediatric Endocrinology Consensus Guidelines of screening, diagnosis and treatment of congenital hypothyroidism. Horm Res Pediatr. 2014;81:80-103.\n\n## 3.2 Hipertiroidismo\n\n### 8. ¿Cuál de los siguientes datos clínicos no es concordante con la enfermedad de Graves?\n\nA. Anticuerpos antilevotiroxina (T4) positivos.\nB. Mixedema pretibial en el 5-10% de los pacientes.\nC. El estrés y el tabaquismo son factores ambientales asociados a la enfermedad.\nD. La manifestación cardiovascular más frecuente es la taquicardia sinusal.\n\nCOMENTARIO\n\nLa enfermedad de Graves es una enfermedad autoinmunitaria cuyas manifestaciones clínicas son debidas a anticuerpos circulantes que se unen al receptor de la TSH, lo que causa hipertiroidismo y bocio. Estos anticuerpos son fundamentalmente IgG1 que se unen a un epítopo rico en leucina del dominio extracelular del receptor de TSH. La sensibilidad y especificidad para detectar enfermed\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}